Eumentis Therapeutics: Funding, Investors & Team (Oct 2026)
A privately held pharmaceutical firm called EuMentis Therapeutics Inc. is working on developing and marketing innovative therapies to treat neuropsychiatric diseases with a high unmet medical need. The most advanced pharmaceutical candidate offered by the company is EM-221, a top-of-the-line oral PDE10A inhibitor that targets the striatum's dopamine D2 pathway. In H2 2023, EuMentis intends to begin EM-221's phase 2 trial for the treatment of Tourette Syndrome. Moreover, EuMentis is creating EM-113, a fast-off, non-competitive NMDA receptor antagonist, to treat people with autism spectrum disorders who have increased brain glutamate levels as detected by MR spectroscopy.
Eumentis Therapeutics has raised $3.0M across 1 funding round on record, the most recent an undisclosed round of $3.0M announced in Feb 2023.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Eumentis Therapeutics Company Profile and Key Stats
Latest funding round on record: Feb 2023.
Eumentis Therapeutics Funding Rounds
Eumentis Therapeutics Founders and Leadership Team
Contact details for the Eumentis Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Eumentis Therapeutics Funding Compared to Other Biotechnology Startups
Eumentis Therapeutics' latest round of $3.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Eumentis Therapeutics in Biotechnology and Boston
Companies Similar to Eumentis Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Eumentis Therapeutics Funding FAQs
What does Eumentis Therapeutics do?
A privately held pharmaceutical firm called EuMentis Therapeutics Inc. is working on developing and marketing innovative therapies to treat neuropsychiatric diseases with a high unmet medical need. The most advanced pharmaceutical candidate offered by the company is EM-221, a top-of-the-line oral PDE10A inhibitor that targets the striatum's dopamine D2 pathway. In H2 2023, EuMentis intends to begin EM-221's phase 2 trial for the treatment of Tourette Syndrome. Moreover, EuMentis is creating EM-113, a fast-off, non-competitive NMDA receptor antagonist, to treat people with autism spectrum disorders who have increased brain glutamate levels as detected by MR spectroscopy.
How much funding has Eumentis Therapeutics raised?
Eumentis Therapeutics has raised $3.0M across 1 round on record. The most recent is an undisclosed round of $3.0M announced in Feb 2023.
When did Eumentis Therapeutics last raise funding?
Eumentis Therapeutics' most recent funding round on record is an undisclosed round of $3.0M, announced in Feb 2023.
Who is the CEO of Eumentis Therapeutics?
Mark Tepper is listed as CEO at Eumentis Therapeutics.
Where is Eumentis Therapeutics headquartered?
Eumentis Therapeutics is based in Boston, Massachusetts, United States.
How many employees does Eumentis Therapeutics have?
Eumentis Therapeutics is in the 1-10 employee band.
How does Eumentis Therapeutics' funding compare to other Biotechnology startups?
Eumentis Therapeutics' latest round of $3.0M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Eumentis Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Eumentis Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.